Journalartikel

Resolvin E1 Improves Mitochondrial Function in Human Alveolar Epithelial Cells during Severe Inflammation


AutorenlisteMayer, Konstantin; Sommer, Natascha; Hache, Karl; Hecker, Andreas; Reiche, Sylvia; Schneck, Emmanuel; Weissmann, Norbert; Seeger, Werner; Hecker, Matthias

Jahr der Veröffentlichung2019

Seiten53-65

ZeitschriftLipids

Bandnummer54

Heftnummer1

ISSN0024-4201

eISSN1558-9307

DOI Linkhttps://doi.org/10.1002/lipd.12119

VerlagWiley


Abstract
Severe inflammatory disorders such as sepsis are a major cause of morbidity and mortality worldwide. Mitochondrial dysfunction is regarded as a key feature involved in inflammation pathogenesis. In the present study, we investigated the impact of the omega-3 fatty acid-derived lipid mediator Resolvin E1 (RvE1) on mitochondrial function in experimental pulmonary inflammation. RvE1 was found to exert anti-inflammatory properties in human alveolar epithelial cells during severe inflammation. RvE1 is capable of restoring inflammation-induced mitochondrial dysfunction and the impaired imbalance of mitochondrial fission and fusion. Experimental inhibition of mitochondrial fission with Mdivi-1 in our model is associated with a significantly reduced inflammatory response and improved mitochondrial function. These findings suggest a novel functional mechanism for the beneficial effects of RvE1 in experimental pulmonary inflammatory reactions.



Zitierstile

Harvard-ZitierstilMayer, K., Sommer, N., Hache, K., Hecker, A., Reiche, S., Schneck, E., et al. (2019) Resolvin E1 Improves Mitochondrial Function in Human Alveolar Epithelial Cells during Severe Inflammation, Lipids, 54(1), pp. 53-65. https://doi.org/10.1002/lipd.12119

APA-ZitierstilMayer, K., Sommer, N., Hache, K., Hecker, A., Reiche, S., Schneck, E., Weissmann, N., Seeger, W., & Hecker, M. (2019). Resolvin E1 Improves Mitochondrial Function in Human Alveolar Epithelial Cells during Severe Inflammation. Lipids. 54(1), 53-65. https://doi.org/10.1002/lipd.12119



Schlagwörter


FISSIONFUSIONLEUKOTRIENE B-4LIPID EMULSIONSResolvin


Nachhaltigkeitsbezüge


Zuletzt aktualisiert 2025-21-05 um 18:26